(Total Views: 1622)
Posted On: 10/31/2024 9:11:17 PM
Post# of 147996
Dr. Palmer / Ascletis :
*Gannex, a wholly owned company of Ascletis Pharma Inc.
*I'm excited about joining Gannex which has three clinical stage assets in NASH, " said Dr. Palmer,
https://www.prnewswire.com/news-releases/gann...81353.html
___
** Gannex also has HIV programs
____
From Dec. 2020–to March 2022 Melissa Palmer, MD was the Chief Medical Officer of Gannex Pharma, a wholly owned company of Ascletis Pharma.
https://liverdisease.com/
___
Her employment history seems to go quiet after that, until
Cytodyn May 24, 2023:
"Mr. Migliarese will be supported by the Company’s recently appointed interim Chief Medical Officer, Dr. Melissa Palmer, ...."
___
Add Dr. Lataillade hiring:
*Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline.
Days later Dr. Palmer hiring:
*In this role, Dr. Palmer will drive the Company’s strategy for research and development in Hepatology,
___
Back to Ascletis:
Ascletis Pharma Inc. is a drug development company in North Carolina that has connections to GlaxoSmithKline (GSK) through its founder and former GSK executive Dr. Jinzi Wu, and former GSK employee Allan Baxter:
Dr. Jinzi Wu
The founder of Ascletis, Dr. Wu was previously the Vice President of Global HIV Drug Discovery at GSK. He has over 20 years of experience in R&D, GMP manufacturing, and commercialization in the biotech and Big Pharma industries.
Allan Baxter
Baxter was the Global Head of Medicines Development at GSK before becoming the Chief Strategy Officer at Ascletis. He has been an advisor to Ascletis since the company's founding.
___
GSK influencing internal moves @ Cytodyn?
If you are in the yes camp, here's another twist/thought:
Late 2021 ViiV acquires the bNab used in our LL-PLS FcRn.
Jan. 25th, 2022 CEO fired.
May 2022 Dr. J outside Scientific Advisor.
Feb. 2023 our 2 key patents from Burger & Chen are granted.
GSK asked Cytodyn / Dr. J to take Interim & possibly into CEO with their backing?
___
Nov. 2023 Dr. J becomes Interim CEO.
Months later, CEO.
Dr. J later says it was a lot with Quest & Cytodyn & wasn't sure, but found he liked being CEO more than expected.
Dr. Lataillade left GSK controlled ViiV to oversee Cytodyn's pipeline & collaborations.
Has GSK been all around, in-directly involved with the Cytodyn turn-around, into 2024 & forward ?
___
Also, when the Pipeline was updated, Katango mentioned it would be nice if each indication had drop-down activity info.
Dr. Palmers words yesterday:
"....and explore new treatments that have the potential to truly transform patient outcomes.”
So far, we have HIV & MASH:
Could later be the start of those sub-attachments.
Ya just never know......
*Gannex, a wholly owned company of Ascletis Pharma Inc.
*I'm excited about joining Gannex which has three clinical stage assets in NASH, " said Dr. Palmer,
https://www.prnewswire.com/news-releases/gann...81353.html
___
** Gannex also has HIV programs
____
From Dec. 2020–to March 2022 Melissa Palmer, MD was the Chief Medical Officer of Gannex Pharma, a wholly owned company of Ascletis Pharma.
https://liverdisease.com/
___
Her employment history seems to go quiet after that, until
Cytodyn May 24, 2023:
"Mr. Migliarese will be supported by the Company’s recently appointed interim Chief Medical Officer, Dr. Melissa Palmer, ...."
___
Add Dr. Lataillade hiring:
*Dr. Lataillade will lead the Company’s global research and development strategy and oversee end-to-end R&D activities to advance the Company’s clinical development pipeline.
Days later Dr. Palmer hiring:
*In this role, Dr. Palmer will drive the Company’s strategy for research and development in Hepatology,
___
Back to Ascletis:
Ascletis Pharma Inc. is a drug development company in North Carolina that has connections to GlaxoSmithKline (GSK) through its founder and former GSK executive Dr. Jinzi Wu, and former GSK employee Allan Baxter:
Dr. Jinzi Wu
The founder of Ascletis, Dr. Wu was previously the Vice President of Global HIV Drug Discovery at GSK. He has over 20 years of experience in R&D, GMP manufacturing, and commercialization in the biotech and Big Pharma industries.
Allan Baxter
Baxter was the Global Head of Medicines Development at GSK before becoming the Chief Strategy Officer at Ascletis. He has been an advisor to Ascletis since the company's founding.
___
GSK influencing internal moves @ Cytodyn?
If you are in the yes camp, here's another twist/thought:
Late 2021 ViiV acquires the bNab used in our LL-PLS FcRn.
Jan. 25th, 2022 CEO fired.
May 2022 Dr. J outside Scientific Advisor.
Feb. 2023 our 2 key patents from Burger & Chen are granted.
GSK asked Cytodyn / Dr. J to take Interim & possibly into CEO with their backing?
___
Nov. 2023 Dr. J becomes Interim CEO.
Months later, CEO.
Dr. J later says it was a lot with Quest & Cytodyn & wasn't sure, but found he liked being CEO more than expected.
Dr. Lataillade left GSK controlled ViiV to oversee Cytodyn's pipeline & collaborations.
Has GSK been all around, in-directly involved with the Cytodyn turn-around, into 2024 & forward ?
___
Also, when the Pipeline was updated, Katango mentioned it would be nice if each indication had drop-down activity info.
Dr. Palmers words yesterday:
"....and explore new treatments that have the potential to truly transform patient outcomes.”
So far, we have HIV & MASH:
Could later be the start of those sub-attachments.
Ya just never know......
(9)
(0)Scroll down for more posts ▼
